Trulieve Cannabis Corp (TRLV)

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Trulieve Cannabis Corp is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.

Trulieve Cannabis Corp is a vertically integrated cannabis company operating retail dispensaries, cultivation facilities, and manufacturing operations across nine states. The company cultivates and processes cannabis products distributed through its branded retail locations under proprietary and partner brands. Trulieve serves medical and adult-use customers through multiple dispensaries organized into regional hubs across the Southeast, Northeast, and Southwest.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Trulieve Cannabis Corp stock.

Our verdict on TRLV

Slightly undervalued: intrinsic value $11.43 per share, market price $10.07, margin of safety 11.9% (as of 2026-11-17).

Discounting its cash flows at 12.6% (average of 2 methods) values the shares at $11.43; the price of $10.07 is 12% below that value, and 65% of that value comes from beyond year five.

More on TRLV

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than TRLV in Drug Manufacturers - Specialty & Generic

6 more in this industry show a wider margin of safety.

Is TRLV undervalued or overvalued?

TRLV is slightly undervalued (as of the 2026-11-17 close). Discounting its cash flows at 12.6% (average of 2 methods) values the shares at $11.43; the price of $10.07 is 12% below that value, and 65% of that value comes from beyond year five.

What is the intrinsic value of TRLV?

$11.43 per share (as of the 2026-11-17 close), against a market price of $10.07. That is a margin of safety of 11.9%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.